EVEREST data on use of tolvaptan published in JAMA and featured at ACC

patients," said Cesare Orlandi, M.D., vice president of Clinical Development at Otsuka Pharmaceutical Development & Commercialization, Inc.

Safety Data

Common adverse events associated with tolvaptan were dry mouth and thirst, which are consistent with the pharmacologic effects of the drug. In the EVEREST trial, adverse events resulting in study drug discontinuation occurred in 6.5 percent of tolvaptan patients and 5.5 percent of placebo patients. Among these, only thirst occurred significantly more frequently with tolvaptan (n equal to 7) vs. placebo (n equal to 0); (p equal to 0.02). Dry mouth resulted in discontinuation in 4 tolvaptan patients vs. 0 placebo patients (p equal to 0.12).

Hypernatremia occurred in 1.7 percent of tolvaptan patients, compared to 0.5 percent of placebo patients. The incidence of kidney failure and low blood pressure were comparable in the two groups. Tolvaptan-treated patients showed no differences from placebo-treated patients with regards to heart rate and blood pressure. In addition, tolvaptan demonstrated no deleterious effects on renal function relative to placebo in these patients.


EVEREST is a landmark, prospective, international, multicenter, randomized, double-blind, placebo-controlled trial conducted at 432 sites in North America, South America and Europe between 2003 and 2006. EVEREST investigators randomized patients with worsening congestive heart failure and who had a left ventricular ejection fraction (LVEF) of 40 percent or less within 48 hours of their hospitalization to receive either 30 milligrams (mg) tolvaptan once-daily or a placebo until the end of the long-term outcome trial. Additionally, treating physicians could choose conventional therapies for their patients, including diuretics, digoxin, ACE inhibitors, angiotensin II receptor blockers, aldosterone blockers, -blockers, nitrates, nesiritide and/or hydralazine.

"EVEREST adds to

Contact: Debra Kaufmann
Porter Novelli

Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:

(Date:8/9/2018)... COSTA MESA, Calif. (PRWEB) , ... August 09, ... ... treatment, officially announces LegitScript certification. LegitScript is a new verification process that substance ... Longridge said, “Being LegitScript certified means we can reach more people to help.” ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks to the ... company’s independent distributors, customers, and employees, the newly established Isagenix Legacy Foundation ... $2 million goal. 100 percent of the donations will fund grants to nonprofit ...
(Date:8/7/2018)... ... 07, 2018 , ... Today Springfield Creamery added six new ... cream-on-top-style yogurts are made with milk from grass-fed cows who enjoy a diet ... acids. Nancy’s sources the milk from organic family-owned farms, all within 60 miles ...
(Date:8/3/2018)... ... ... On August 2, 2018 the JPML ordered that the Zostavax MDL be ... has been litigating Zostavax injuries since 2011. , On ... the thousands of people injured by Zostavax, a vaccine given to adults to prevent ...
(Date:8/2/2018)... ... 02, 2018 , ... Dr. Srini Pillay , best-selling author of ... people could care less, demonstrating a “whatever” attitude toward life, people, and situations around ... one often overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition ...
Breaking Medicine News(10 mins):
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... CBD Day with Charlotte-area company cbdMD named the exclusive sponsor. , “We’re honored ... exciting to see such public embrace for CBD on a national level,” said ...
(Date:8/7/2018)... ... August 07, 2018 , ... Commissioner Gottlieb’s FDA:, Analysis of First ... – 3:00 p.m. ET, http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes ... have benefited, some may have gotten hurt. , And Gottlieb is just getting started. ...
(Date:8/7/2018)... PLEASANTON, Calif. (PRWEB) , ... ... ... Chief Executive Officer, today announced the appointment of Richard A. Stark to assume the role of Sanarus ... will apply his 20+ years of strategic development, marketing and sales experience in medical ...
Breaking Medicine Technology:
Cached News: